Author

Fabien Ricard

Observed names: F Ricard, F. Ricard, Fabien Jean Ricard, RICARD, Fabien

Observed institutions: Lyon 1 Université, Université de Lyon, Hospices Civils de Lyon, Centre Léon Bérard, Hôpital Lyon Sud, Relay Therapeutics (United States), Centre pour l'innovation en cancérologie de Lyon

ORCID: 0000-0003-1287-8075

Observed ORCID: 0000-0003-1287-8075

OpenAlex ID: A5070966637

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies

2014 · Judith Trotman, Stefano Luminari, et al. · The Lancet Haematology · 182

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

2023 · Vivek Subbiah, Vaibhav Sahai, et al. · Cancer Discovery · 127

PDF

Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric Rhabdomyosarcoma

2011 · Fabien Ricard, Sébastien Cimarelli, et al. · Clinical Nuclear Medicine · 83

Computer-Aided Staging of Lymphoma Patients With FDG PET/CT Imaging Based on Textural Information

2013 · C. Lartizien, M. Rogez, et al. · IEEE Journal of Biomedical and Health Informatics · 77

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)

2022 · Fabien Ricard, Bruce Cheson, et al. · Journal of Nuclear Medicine · 53

PDF

PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study

2014 · Christelle Tychyj-Pinel, Fabien Ricard, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 48

Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

2023 · Mitesh J. Borad, Alison M. Schram, et al. · Journal of Clinical Oncology · 40

Computer aided staging of lymphoma patients with FDG PET/CT imaging based on textural information

2012 · Carole Lartizien, Matthieu Rogez, et al. · IEEE International Symposium on Biomedical Imaging (ISBI) · 18

Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study

2023 · Alison M Schram, Vivek Subbiah, et al. · Molecular Cancer Therapeutics · 13

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical)

2022 · Fabien Ricard, Sally Barrington, et al. · Journal of Nuclear Medicine · 11

PDF

PET-CT and diagnostic CT: The synergy of metabolic and morphological data in onco-haematology

2013 · F. Ricard, F. Giammarile, et al. · Diagnostic and Interventional Imaging · 9

PDF

Hibernoma: Don’t be caught out by a PET scan!

2013 · A. Ognong Boulemo, J.-A. Roch, et al. · Diagnostic and Interventional Imaging · 8

PDF

Feasibility of iodine contrast enhanced CT-scan during a 18F-fluorodeoxyglucose Positron Emission Tomography

2009 · C Houzard, C Tychyj, et al. · Journal of Instrumentation · 5

PDF

A Case of Advanced Non-Hodgkin's Lymphoma Involving the Prostate

2010 · Sébastien Cimarelli, Florence Lachenal, et al. · Clinical Nuclear Medicine · 4

58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study

2024 · A. Hollebecque, E. Dotan, et al. · European Journal of Cancer · 3

TEP/TDM au FDG et bilan initial des lymphomes : du diagnostic au pronostic

2011 · C. Tychyj-Pinel, F. Ricard, et al. · Médecine Nucléaire · 2

Data from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

2023 · Vivek Subbiah, Vaibhav Sahai, et al. · 1

Abstract OT3-24-01: ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer

2023 · Suneel Kamath, David Tai, et al. · Cancer Research · 1

Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.

2014 · Judith Trotman, Stefano Luminari, et al. · Journal of Clinical Oncology · 1

Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations